New Product Briefs: ReSure Sealant, Direct Flow TAVR; DePuy Spine Device
This article was originally published in The Gray Sheet
Executive Summary
Ocular Therapeutix’s ReSure Sealant gains PMA approval for sealing cataract surgery incisions. Direct Flow gains CE mark for larger version of its repositionable transcatheter aortic valve replacement. More product news.
You may also be interested in...
Ophthalmic Devices Panel Supports Safety For Ocular Therapeutix’ ReSure Sealant, But Other Votes Mixed
The FDA panel voted 9-1 in favor of the safety of Ocular’s PMA Sept. 19, but 5-1 on whether the benefits of the device, an in situ-formed hydrogel that creates an adherent temporary, soft and lubricious sealant to prevent leakage from clear corneal incisions, outweigh its risk, and 5-3 on its effectiveness. Multiple panelists abstained from the last two votes based on concerns with wording of the indication.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.